Journal
AGE AND AGEING
Volume 41, Issue 3, Pages 408-412Publisher
OXFORD UNIV PRESS
DOI: 10.1093/ageing/afr171
Keywords
Alzheimer's disease; biomarker; platelet; immunoglobulin; alpha-synuclein; clusterin; APP; tau; elderly
Categories
Funding
- Alzheimer's Society, London (UK)
- RCUK Newcastle Centre for Brain Ageing and Vitality
- UK NIHR Biomedical Research Centre for Ageing and Age-related disease
- MRC [G0900652, G0502157, G1100540, G0700718, G0400074] Funding Source: UKRI
- Medical Research Council [G0700718, G0502157, G1100540, G0900652, G0400074] Funding Source: researchfish
Ask authors/readers for more resources
Methods: twenty-five subjects with a clinical diagnosis of AD and 26 control participants were assessed for cognitive and behavioural functioning. Platelet measures of amyloid protein precursor (APP), tau protein, clusterin, alpha-synuclein and immunoglobulin (Ig) were measured. Linear regression analysis for platelet proteins and cognitive and behavioural status were determined, and receiver operating characteristic (ROC) curves created to assess the discriminating power of each biochemical parameter between AD and control groups. Results: both AD and control subjects had similar platelet levels of measures platelet proteins, with the exception of slightly elevated Ig levels in AD subjects (P = 0.052). The latter were not related to increasing age, or extent of cognitive impairment. APP-N measures were negatively correlated with cognitive scores. Conclusion: these preliminary findings suggest that platelet measures of the traditional biomarkers for AD are feasible in the periphery. The measures of platelet APP-N and Ig, in particular, merit further study in a larger cohort of AD and control subjects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available